Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Upper limb spasticity~* Time since stroke greater than 3 months~* Need for 400 U Botulinum toxin type A~Exclusion Criteria:~* Body weight below 50kg~* Fixed contractures of the upper limb~* Generalized disorders of muscle activity like Myasthenia gravis that preclude use of Botulinum toxin Type A~* Infection at the injection site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DB IncobotulinumtoxinA (Xeomin) (400 U) (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
- DB Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment

Based on this trial design, predict the completion outcome and termination type (if applicable).